Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been shown to significantly increase survival benefits in terms of progression-free survival and overall survival (OS), but the evidence on treating older women with metastatic BC is limited. This evidence concerns the gene CDK4 and breast cancer.